Hypotensive reactions to white cell-reduced plasma in a patient undergoing angiotensin-converting enzyme inhibitor
Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor
in non-diabetic renal disease (COOPERATE): a randomised controlled clinical trial.
Effect of the angiotensin-converting enzyme inhibitor
benazepril on the progression of chronic renal insufficiency.
Cardiorenal protective effects of yearlong antihypertensive therapy with a angiotensin-converting enzyme inhibitor
or a calcium channel blocker in spontaneously hypertensive rat.
Key Words: heart failure, left ventricular dysfunction, angiotensin-converting enzyme inhibitors
, beta blockers, aldosterone antagonists, angiotensin-receptor blockers, digoxin
Importance of angiotensin-converting enzyme inhibitors
in myocardial infarction and congestive heart failure: implications for clinical practice.
As such, it would be prescribed only if symptoms persisted after the use of such drugs as angiotensin-converting enzyme inhibitors
and beta blockers, which reduce the risk of hospitalization and death.
In addition to the AIIRAs, these drug classes include angiotensin-converting enzyme inhibitors
(ACEIs), calcium-channel blockers (CCBs) and diuretics.
The patient was prescribed by angiotensin-converting enzyme inhibitors
, beta-blockers, warfarin, statins and diuretics.
In both study groups, additional antihypertensive drug treatment, other than ARBs or angiotensin-converting enzyme inhibitors
, was used to reach the target blood pressure of less than 130/80 mm Hg, Dr.
By 2019, the drug classes typically used as first-, second-, and third-line therapy will all be subject to generic competition - these drug classes are the angiotensin-converting enzyme inhibitors
(ACEIs), angiotensin II receptor antagonists (AIIRA), calcium channel blockers (CCBs) and diuretics.
Drugs that prevent ischemic events, or lessen their impact, such as anticoagulants, statins, angiotensin-converting enzyme inhibitors
, and aldosteron antagonists, all reduce the incidence of sudden death.
With regard to antihypertensive drugs, 53% were receiving angiotensin-converting enzyme inhibitors
, 28% diuretics, 17% angiotensin II receptor blockers, 14% [beta]-adrenergic blocking agents, 12% calcium channel blockers, and 1% [alpha]-adrenergic blocking agents.
Forty-one percent were taking angiotensin-converting enzyme inhibitors
and 29% were taking calcium channel blockers.
Examples of such differences that have already been observed in trials include the finding that hypertensive black patients do not respond as well to [beta]-blockers or angiotensin-converting enzyme inhibitors